Brief: Immutep Gets FDA Nod to Advance Eftilagimod Alfa in Head & Neck Cancer (CPS <1)
05/08/2025 14:10
Aug 5 (Reuters) - Immutep Ltd IMM.AX: IMMUTEP RECEIVES POSITIVE FEEDBACK FROM FDA ON LATE-STAGE CLINICAL DEVELOPMENT OF EFTILAGIMOD ALFA IN HEAD AND NECK CANCER WITH CPS <1 Source text: ID:nGNX7D2Mb8 Further company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))